Research Proposal

Formulation and Clinical Evaluation of a Homoeopathic Hair Serum for the Management and Prevention of Hair Fall and Related Scalp Conditions

1. TITLE PAGE

2. ABSTRACT

3. INTRODUCTION

3.1 Background and Significance

• Non-scarring (reversible): Androgenetic alopecia (AGA), telogen effluvium, alopecia areata, seborrhoeic dermatitis-related hair loss
• Scarring (irreversible): Lichen planopilaris, discoid lupus, folliculitis decalvans
• Traumatic/exogenous: Traction alopecia, chemical damage

3.2 Hair Cycle Physiology

• Anagen (growth phase): 3-5 years for scalp hair; actively dividing matrix cells in the hair bulb
• Catagen (regression phase): 2-3 weeks; controlled apoptosis of follicular keratinocytes
• Telogen (resting phase): 3 months; hair shaft retained until new anagen begins
• Exogen (shedding): Active shedding of the club hair

3.3 Limitations of Conventional Treatments

• Topical minoxidil (2-5%): Prolongs anagen and increases follicular size; requires lifelong use; side effects include scalp irritation, hypertrichosis, and potential cardiovascular effects with oral forms
• Oral finasteride/dutasteride: 5α-reductase inhibitors; sexual side effects, contraindicated in women of childbearing age
• JAK inhibitors (baricitinib, ritlecitinib): For alopecia areata; expensive, immunosuppressive risk profile
• Platelet-rich plasma (PRP): Procedural, costly, variable evidence

3.4 Rationale for Homoeopathic Formulation

3.5 Anti-inflammatory Evidence for Arnica

4. AIMS AND OBJECTIVES

4.1 Primary Aim

4.2 Specific Objectives

1. To prepare and characterize (physicochemical evaluation) a homoeopathic hair serum using mother tinctures of Arnica montana, Pilocarpus jaborandi, Cantharis vesicatoria, Calendula officinalis, Emblica officinalis (Amla), and Bacopa monnieri
2. To evaluate the effect of the serum on hair cycle parameters - anagen:telogen ratio and hair density - using TrichoScan® digital trichoscopy
3. To quantify reduction in daily hair fall (daily hair count method)
4. To assess improvement in scalp conditions (dandruff, seborrhoea, pruritus, erythema) by dermatological grading
5. To evaluate changes in hair tensile strength and thickness
6. To assess impact on patient quality of life using the Dermatology Life Quality Index (DLQI)
7. To document the safety and tolerability of the formulation

5. REVIEW OF LITERATURE

5.1 Hair Follicle Biology and Alopecia

5.2 Homoeopathic Materia Medica for Hair Conditions

• Inhibition of NF-κB-mediated inflammatory cascade (anti-inflammatory)
• Increased local microcirculation by vasodilatory sesquiterpenes
• Sebum regulation and antimicrobial activity (anti-dandruff)
• Reduction of scalp inflammation that impairs follicular cycling PMID 37598770 confirms in-vitro anti-inflammatory activity.

• Stimulates sweat and sebaceous glands, enhancing scalp microcirculation
• May activate dermal papilla cells
• Traditional homoeopathic indication: hair loss, premature baldness, excessive dandruff, greying

• Increases local blood flow through mild vesicant action
• Stimulates follicular activity and keratinocyte proliferation
• Traditionally indicated for alopecia with scalp irritation, vesicular scalp conditions
• Used in very low concentrations in topical preparations to avoid irritation

• Potent wound healing and anti-inflammatory properties
• Promotes scalp epithelial healing and reduces seborrhoeic inflammation
• Antimicrobial activity against Malassezia species (a key dandruff pathogen)
• Soothes scalp pruritus and erythema

• Potent antioxidant, reducing oxidative damage to hair follicle cells
• Inhibits 5α-reductase activity (DHT-lowering), relevant to AGA
• Promotes melanin synthesis in hair follicle melanocytes (anti-greying)
• Saberry® (standardised E. officinalis extract) was a key ingredient in the PMC7522433 clinical study showing significant hair density improvement

• Reduces cortisol-mediated stress-induced hair loss (adaptogenic/anti-stress)
• Antioxidant: reduces H2O2-induced follicular apoptosis
• Promotes cerebral and peripheral microcirculation
• Traditional Ayurvedic-homoeopathic use for nervous debility, stress-related hair fall

5.3 Previous Clinical Studies

6. MATERIALS AND METHODS

6.1 Study Design

• Type: Open-label, single-arm, prospective clinical evaluation
• Duration: 90 days treatment + 30-day post-treatment follow-up (Day 120)
• Assessment visits: Day 0 (baseline), Day 30, Day 60, Day 90, Day 120 (follow-up)
• Setting: Department of Pharmacy / Clinical Research Centre, [Institution Name]
• Ethics Approval: Required from the Institutional Ethics Committee (IEC) prior to subject enrolment, in accordance with ICMR National Ethical Guidelines for Biomedical and Health Research 2017, and the Declaration of Helsinki (2013 revision)
• Registration: Trial to be registered on the Clinical Trials Registry-India (CTRI) prior to enrolment

6.2 Formulation of Homoeopathic Hair Serum

6.2.1 Source of Ingredients

6.2.2 Proposed Formulation (per 100 mL serum)

6.2.3 Preparation Method

1. Measure all mother tinctures accurately using calibrated glass pipettes
2. Dissolve Cosmoperine®, allantoin, and panthenol in a portion of distilled water (heated to 40°C) with constant stirring
3. Add tocopherol acetate to the aqueous phase with gentle mixing
4. Combine mother tinctures with the 10% ethanol component; mix thoroughly
5. Slowly add the ethanolic mother tincture blend to the aqueous excipient base with continuous stirring
6. Add preservative; adjust volume to 100 mL with distilled water
7. Adjust pH to 5.5-6.5 using citric acid or triethanolamine as needed
8. Filter through a 0.45 µm membrane filter; fill into amber glass dropper bottles (50 mL)
9. Label per HPI guidelines; store at 25°C ± 2°C, away from direct sunlight

6.3 Physicochemical Evaluation of the Formulation

6.4 Study Subjects

6.4.1 Inclusion Criteria

1. Healthy male and female volunteers aged 20-50 years
2. Self-reported hair fall for at least 3 months
3. Hair loss grade 3-6 on the 10-point photo-numeric Hamilton-Norwood (male) or Ludwig (female) scale
4. Hair density 100-200 follicles/cm² by TrichoScan® at baseline
5. Willing to provide written informed consent
6. Agreeing to use only the provided neutral study shampoo (≤3 times/week)
7. Agreeing to refrain from other hair treatments (colouring, perming, spa, oil treatments, laser) during the study

6.4.2 Exclusion Criteria

1. Known hypersensitivity to any component of the formulation or plants in Asteraceae family (relevant to Arnica and Calendula)
2. Pregnancy, lactation, or planning pregnancy during the study period
3. Diagnosed scarring alopecia, autoimmune alopecia totalis/universalis, or alopecia secondary to chemotherapy
4. Active scalp infections (bacterial, fungal), open wounds, or psoriasis of the scalp
5. Use of finasteride, dutasteride, minoxidil, or any other anti-hair loss medication within 3 months of enrolment
6. Current use of immunosuppressants, systemic corticosteroids, or anticoagulants
7. Participation in another clinical study within the preceding 3 months
8. Active smokers or history of heavy alcohol use (>21 units/week)
9. Crash dieting or severe nutritional restriction
10. Thyroid dysfunction (active or poorly controlled), iron deficiency anaemia (documented)
11. Dermatological conditions (eczema, psoriasis) affecting scalp

6.4.3 Sample Size

• Z_α (two-tailed, 0.05) = 1.96
• Z_β (power 80%) = 0.84
• Expected effect size (δ) and SD (σ) derived from pilot/reference data

6.5 Study Procedure

6.5.1 Washout Period

6.5.2 Treatment Administration

• Dose: 2 mL (males) / 3 mL (females) once daily (evening/night application)
• Method: Hair parted into sections; serum applied directly to scalp using dropper, distributed with fingertip massage in circular motion for 5 minutes; leave-in (do not rinse)
• Duration: 90 days continuous use

6.5.3 Visit Schedule

6.6 Outcome Measures

6.6.1 Primary Outcomes

1. Anagen:Telogen (A:T) ratio - by TrichoScan® Pro digital trichoscopy (FotoFinder Systems), measured in a standardized 1 cm² shaved scalp area (vertex)
2. Hair density (total follicles/cm²) - by TrichoScan®
3. Daily hair fall count - subjects collect shed hairs on Days 0, 30, 60, 90 using standardised comb/pillow collection protocol over 3 consecutive days per assessment window

6.6.2 Secondary Outcomes

1. Hair thickness (mean hair shaft diameter in µm) - by TrichoScan®
2. Hair growth rate (µm/day) - by TrichoScan® (2-day interval measurement)
3. Terminal vs. vellus hair density - by TrichoScan® (terminal: ≥40 µm; vellus: <40 µm)
4. Scalp condition dermatological assessment - graded 0-3 scale for: dandruff/scaling, seborrhoea, pruritus, erythema, roughness, and dryness
5. Hair tensile strength - by standardised hair pull test (positive/negative) and trichometric measurement (if available)
6. Global photographic assessment - standardised scalp photography (Canfield VEOS Hair system or equivalent); assessed by two independent blinded dermatologists using a 7-point Global Improvement Scale
7. DLQI (Dermatology Life Quality Index) - validated 10-item questionnaire (Finlay & Khan, 1994)
8. Subject self-assessment - 5-point Likert scale for overall appearance, volume, density, and satisfaction

6.6.3 Safety Outcomes

• Adverse events (AEs) and serious adverse events (SAEs) - reported at each visit
• Local tolerability: erythema, oedema, vesiculation, burning, pruritus (graded 0-3)
• Vital signs (blood pressure, pulse) at screening and end-of-treatment visit

6.7 Statistical Analysis

• Software: SPSS v25 / GraphPad Prism
• Descriptive statistics: Mean ± SD for continuous variables; frequency and percentage for categorical variables
• Primary analysis: Paired t-test (two-tailed) comparing outcome measures at Days 30, 60, 90, and 120 vs. Day 0 (baseline)
• Non-parametric alternative: Wilcoxon signed-rank test if normality assumption violated (Shapiro-Wilk test, p<0.05)
• Repeated measures analysis: One-way repeated-measures ANOVA with Bonferroni post-hoc correction for time-point comparisons
• Significance level: p<0.05 considered statistically significant; p<0.0001 highly significant
• Per-protocol population: All subjects completing at least 80% compliance

7. ETHICAL CONSIDERATIONS

1. The study will be conducted after obtaining approval from the Institutional Ethics Committee (IEC) per ICMR guidelines and the Declaration of Helsinki
2. All subjects will provide written informed consent in their vernacular language prior to any study procedure
3. Subjects may withdraw from the study at any time without consequence to their care
4. Confidentiality of subject data will be maintained; data will be coded and anonymised
5. Insurance/compensation will be provided for any study-related adverse events
6. The formulation will be shown to be non-irritant by HET-CAM testing prior to use in humans
7. Subjects with evidence of allergic reaction at any visit will be immediately withdrawn and referred for appropriate dermatological care

8. EXPECTED OUTCOMES AND SIGNIFICANCE

9. LIMITATIONS

1. Open-label design without a placebo control arm limits ability to account for placebo effect and natural hair cycle variation; a future RCT with placebo or active comparator (topical minoxidil) arm is recommended
2. Single-centre study may limit generalisability
3. Lack of blinding for investigators at clinical assessments (mitigated by independent blinded photographic review)
4. Standardisation of homoeopathic mother tincture batches requires ongoing quality control; inter-batch variability is a potential confound
5. Absence of serum drug-level (pharmacokinetic) data due to the complex multi-component nature of mother tinctures

10. FUTURE DIRECTIONS

• Phase II double-blind, placebo-controlled RCT with parallel arms (serum vs. minoxidil vs. placebo)
• Inclusion of trichoscopy (dermoscopy) for scarring vs. non-scarring differentiation at enrolment
• Molecular biomarker sub-study: serum DHT, scalp biopsy for follicular miniaturisation grading, oxidative stress markers (8-OHdG)
• Separate arms for AGA vs. telogen effluvium to characterise differential response
• Economic analysis and accessibility study for low-income population contexts

11. REFERENCES

1. Bhadoriya, D.Y.S. (2023). Clinical trial to assess the safety and efficacy of hair grow serum product in volunteers with hair fall and healthier hair. International Journal of Herbal Medicine, 11(4). doi:10.22271/FLORA.2023.V11.I4A.870
2. Shankar E. et al. (2020). Clinical Study to Evaluate the Efficacy and Safety of a Hair Serum Product in Healthy Adult Male and Female Volunteers with Hair Fall. [PMC7522433] Clinical, Cosmetic and Investigational Dermatology.
3. Piraccini BM et al. (2022). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. [PMID: 34634163]
4. Rossi A, Caro G (2024). Efficacy of topical minoxidil and topical finasteride in men with androgenetic alopecia. J Cosmet Dermatol. [PMID: 37798906]
5. Sudeep HV et al. (2023). Oral and Topical Administration of a Standardized Saw Palmetto Oil Reduces Hair Fall and Improves the Hair Growth in Androgenetic Alopecia. Clin Cosmet Investig Dermatol. [PMID: 38021422]
6. Yerram C et al. (2023). Effects of Withania somnifera root extract serum on hair health. J Ayurveda Integr Med. [PMID: 38006746]
7. Verre J, Boisson M, Paumier A et al. (2024). Anti-inflammatory effects of Arnica montana in various cell models. J Ethnopharmacol. [PMID: 37598770]
8. Bhasme A, Lamba P, Sajjan U (2023). A Case Report of Alopecia Areata Treated with Individualized Homoeopathy. Altern Ther Health Med. [PMID: 34653026]
9. Anusha R et al. (2023). Formulation and evaluation of herbal hair serum - a review. Int J Basic Clin Pharmacol, 12(5):759-765.
10. Ito T et al. (2021). Hair Follicle Physiology and Hair Cycle. In: Fitzpatrick's Dermatology, 9th Ed. McGraw-Hill.
11. Bergfeld WF (2022). Hair Loss and Alopecias. In: Goldman-Cecil Medicine, International Edition, Vol 2.
12. Elston DM, James WD (2019). Andrews' Diseases of the Skin: Clinical Dermatology, 13th Ed. Elsevier.
13. Griffiths C, Barker J, Bleiker T et al. (2021). Rook's Dermatology / Dermatology 2-Volume Set 5e.
14. Finlay AY, Khan GK (1994). Dermatology Life Quality Index (DLQI). Clin Exp Dermatol.
15. Homoeopathic Pharmacopoeia of India (HPI), Ministry of AYUSH, Government of India.
16. ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017).

APPENDICES